Navigation Links
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
Date:6/4/2008

SAN DIEGO, June 4 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present the corporate overview on Wednesday, June 11, 2008 at 3:00 pm Eastern Time (12:00 pm Pacific Time) during the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference at the New York Palace Hotel in New York City.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 90 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

Contacts: William R. LaRue Anna Gralinska

SVP & Chief Financial Officer Director, Investor Relations

Cadence Pharmaceuticals, Inc. Cadence Pharmaceuticals, Inc.

858-436-1400 858-436-1452


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
2. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
3. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
4. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
5. Antipodean Pharmaceuticals Announces FDA Acceptance of IND for MitoQ(R)
6. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
7. Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
8. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
9. Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
10. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
11. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... ... as an employee health benefit for companies that want to help members of ... providers, employees will have access to Watson’s suite of oncology offerings for insights ...
(Date:2/20/2017)... Orlando, FL (PRWEB) , ... February 20, 2017 ... ... company for eye care providers and health plan partners, announced during the 2017 ... the organization’s success enhancing care coordination for diabetic patients and integrating eye ...
(Date:2/19/2017)... ... February 19, 2017 , ... ... result in better care, and MEDfx and the Delaware Health Information Network (DHIN) ... , As the nation’s first state-wide health information exchange, DHIN stores and shares ...
(Date:2/18/2017)... Hills, California (PRWEB) , ... February 17, 2017 ... ... info@drvallecillos.com , drvallecillos.com , Beverly Hills plastic surgeon Dr. ... subcutaneous fat cells. , Dr. Vallecillos says, "Traditionally, plastic surgery has been centered ...
(Date:2/17/2017)... ... February 17, 2017 , ... While ... Enovate Medical has introduced an innovative workstation designed to reduce nursing fatigue while ... Encore Mobile EHR Workstation offers a lightweight, highly mobile, multi-functional alternative to the ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... Acute, Chronic and Prophylaxis GVHD The global graft versus host ... 2016-2021 and CAGR of 3% from 2021-2027. The market is expected to ... is estimated at $0.36bn in 2016, $0.51bn in 2021, and $0.64bn in ... How this report will ... future business opportunities emerging in this sector. In this brand ...
(Date:2/19/2017)...  nThrive™, an independent Patient-to-Payment? solutions company will ... at the 2017 HIMSS Conference. The company will ... KLAS. nThrive will host a Lunch ... trends shape the holistic, integrated revenue cycle of ... Access solution. The panel will reveal how health ...
(Date:2/19/2017)... and ORLANDO, Fla. , Feb. ... NKTR ) today announced that positive Phase 1 clinical ... with renal cell carcinoma (RCC) were presented at ASCO ... to expand specific cancer-fighting T cells and Natural Killer ... increase expression of PD-1 on these immune cells.  The ...
Breaking Medicine Technology: